Merck Halts Alzheimer’s Drug MK-1167 Due to Lack of Efficacy; HuaHui AnJian Launches Phase I Trial of PD-1/VEGFA/CTLA4 Trispecific Antibody HH160
Huahui Health
Innovative Drug Developer
Argo
RNAi Drug Developer
Qyuns
Developer of Biologics for Autoimmune and Allergic Diseases
AstraZeneca
Pharmaceutical Technology Research and Development Provider
Amino Observation – Original Content by the Innovative Drug Group
Author | Huang Kai
Alzheimer's Drug Development Is Challenging.
On July 1, Merck updated the status of a study on ClinicalTrials.gov, terminating a Phase II clinical trial (MK-1167-008) of its small-molecule Alzheimer’s disease candidate drug MK-1167. Merck disclosed to Fierce that the termination was due to efficacy falling short of expectations and failing to meet the criteria for continued development, and that the decision was unrelated to drug safety.
Another PD-1/VEGF-A/CTLA-4 Trispecific Antibody Initiates Clinical Trials.
Recently, according to the official website of the Drug Clinical Trial Registration and Information Publicity Platform, Huahui Health has registered an open-label, multicenter, Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of HH160 as monotherapy or in combination with other anti-tumor drugs in patients with advanced or metastatic solid tumors.
What other hot topics in the domestic and international pharmaceutical markets are worth paying attention to over the past day? Let Amin Jun take you to explore.
/ 01 /
Market Flash
1) Harbour BioMed Appoints New Chief Operating Officer
On July 3, Harbour BioMed announced the appointment of Dr. Wang Peng as Chief Operating Officer (COO). Dr. Wang will be based in Suzhou and will report directly to Dr. Hong Di, CEO of Harbour BioMed.
/ 02 /
Pharmaceutical News
1) Eli Lilly's selpercatinib proposed for priority review
On July 2, according to the official website of the Center for Drug Evaluation (CDE), Eli Lilly’s selpercatinib is proposed for inclusion in the priority review program for adjuvant treatment following curative-intent local therapy in patients with stage IB to IIIA non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) gene fusions. This indication has not yet been approved globally.
2) Huahui Health Initiates First-in-Human Clinical Trial for PD-1/VEGFA/CTLA-4 Trispecific Antibody
Recently, according to the official website of the Drug Clinical Trial Registration and Information Publicity Platform, Huahui Health has registered an open-label, multicenter, Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of HH160 as monotherapy or in combination with other anti-tumor drugs in patients with advanced or metastatic solid tumors.
3) Argo Biopharma’s BW-50920 Injection Receives Clinical Trial Approval
On July 2, according to the official website of the Center for Drug Evaluation (CDE), Argo Biopharma’s BW-50920 injection received clinical trial approval. It is intended for the treatment of complement-mediated kidney diseases, including primary focal segmental glomerulosclerosis (FSGS), C3 glomerulopathy (C3G), and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
4) Qyuns’ CLD-423 Injection Receives Clinical Trial Approval
On July 2, according to the official website of the Center for Drug Evaluation (CDE), Qyuns’ CLD-423 injection received clinical trial approval, with plans to conduct research on the treatment of Crohn’s disease.
5) AstraZeneca’s Elecoglipron Film-Coated Tablets Receive Clinical Trial Approval
On July 2, according to the official website of the Center for Drug Evaluation (CDE), AstraZeneca’s Elecoglipron film-coated tablets received clinical trial approval for the treatment of chronic kidney disease in adults.
/ 03 /
Global Pharma News
1) Efficacy Falls Short of Expectations, Merck Terminates a Phase II Clinical Study
On July 1, Merck updated the status of a study on ClinicalTrials.gov, terminating a Phase II clinical trial (MK-1167-008) of its small-molecule Alzheimer’s disease candidate drug, MK-1167. Merck disclosed to Fierce that the termination was due to efficacy falling short of expectations and failing to meet the criteria for continued development, and that this decision was unrelated to drug safety.